Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?

Yeo Jeong So¹, Sophia Frentzas^{1

2}, Eva Segelov^{1

2}

Affiliations

¹ Medical Oncology, Monash Health, Melbourne, Australia.
² Translational Oncology Research Laboratory, Monash University, Melbourne, Victoria, Australia.

Editorial

Yeo Jeong So et al. Hepatobiliary Surg Nutr. 2019 Oct.

. 2019 Oct;8(5):546-548.

doi: 10.21037/hbsn.2019.04.14.

Yeo Jeong So¹, Sophia Frentzas^{1

2}, Eva Segelov^{1

2}

¹ Medical Oncology, Monash Health, Melbourne, Australia.
² Translational Oncology Research Laboratory, Monash University, Melbourne, Victoria, Australia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.

1. Global Burden of Disease Liver Cancer Collaboration , Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91. 10.1001/jamaoncol.2017.3055 - DOI - PMC - PubMed
1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed
1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 10.1016/S1470-2045(08)70285-7 - DOI - PubMed
1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet 2018;391:1163-73. 10.1016/S0140-6736(18)30207-1 - DOI - PubMed
1. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. 10.1016/S0140-6736(16)32453-9 - DOI - PubMed